Glioblastoma (GBM) is the most common kind of malignant brain tumor in adults. In recent years, the tumor microenvironment ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the ...

T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.